A Simplified Score to Quantify Comorbidity in COPD by Putcha, Nirupama et al.
 
A Simplified Score to Quantify Comorbidity in COPD
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Putcha, N., M. A. Puhan, M. B. Drummond, M. K. Han, E. A.
Regan, N. A. Hanania, C. H. Martinez, et al. 2014. “A Simplified
Score to Quantify Comorbidity in COPD.” PLoS ONE 9 (12):
e114438. doi:10.1371/journal.pone.0114438.
http://dx.doi.org/10.1371/journal.pone.0114438.
Published Version doi:10.1371/journal.pone.0114438
Accessed February 17, 2015 8:53:32 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581208
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAARESEARCH ARTICLE
A Simplified Score to Quantify Comorbidity
in COPD
Nirupama Putcha
1*, Milo A. Puhan
2, M. Bradley Drummond
1, MeiLan K. Han
3,
Elizabeth A. Regan
4, Nicola A. Hanania
5, Carlos H. Martinez
3, Marilyn Foreman
6,
Surya P. Bhatt
7, Barry Make
8, Joe Ramsdell
9, Dawn L. DeMeo
10, R. Graham
Barr
11, Stephen I. Rennard
12, Fernando Martinez
13, Edwin K. Silverman
10,
James Crapo
8, Robert A. Wise
1, Nadia N. Hansel
1
1. Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland,
United States of America, 2. Epidemiology, Biostatistics & Prevention Institute, University of Zurich, Zurich,
Switzerland, 3. Pulmonary & Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, United
States of America, 4. Department of Medicine, National Jewish Health, Denver, Colorado, United States of
America, 5. Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas, United
States of America, 6. Pulmonary and Critical Care Medicine, Morehouse School of Medicine, Atlanta,
Georgia, United States of America, 7. Pulmonary, Allergy and Critical Care Medicine, University of Alabama at
Birmingham, Birmingham, Alabama, United States of America, 8. Pulmonary and Critical Care, National
Jewish Health, Denver, Colorado, United States of America, 9. Pulmonary and Critical Care Medicine,
University of California San Diego, San Diego, California, United States of America, 10. Channing Division of
Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United
States of America, 11. Department of Medicine, Department of Epidemiology, Columbia University Medical
Center, New York City, New York, United States of America, 12. Pulmonary and Critical Care Medicine,
University of Nebraska Medical Center, Omaha, Nebraska, United States of America, 13. Pulmonary and
Critical Care Medicine, New York Presbyterian-Weill Cornell Medical College, New York City, New York,
United States of America
*Nputcha1@jhmi.edu
Abstract
Importance: Comorbidities are common in COPD, but quantifying their burden is
difficult. Currently there is a COPD-specific comorbidity index to predict mortality
and another to predict general quality of life. We sought to develop and validate a
COPD-specific comorbidity score that reflects comorbidity burden on patient-
centered outcomes.
Materials and Methods: Using the COPDGene study (GOLD II-IV COPD), we
developed comorbidity scores to describe patient-centered outcomes employing
three techniques: 1) simple count, 2) weighted score, and 3) weighted score based
upon statistical selection procedure. We tested associations, area under the Curve
(AUC) and calibration statistics to validate scores internally with outcomes of
respiratory disease-specific quality of life (St. George’s Respiratory Questionnaire,
SGRQ), six minute walk distance (6MWD), modified Medical Research Council
(mMRC) dyspnea score and exacerbation risk, ultimately choosing one score for
external validation in SPIROMICS.
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Data Availability: The authors confirm that, for
approved reasons, some access restrictions apply
to the data underlying the findings. All the data sets
in this study are available as indicated below. The
COPDGene data upon which these findings are
based are available through the dbGaP study page
for COPDGene: http://www.ncbi.nlm.nih.gov/
projects/gap/cgi-bin/study.cgi?study_
id5phs000179.v3.p2. There is a link from this
page (Authorized Access Section) to dbGaP’s
controlled access system that allows someone to
request the data. The accession number for this
data is phs000179.v3.p2. The SPIROMICS study
can provide datasets upon submission and
approval of the Data Access Request Form as
per the study policy. Available data and forms can
be found at the following link: http://www.cscc.unc.
edu/spir/public/docfilter.php?study5spir&filter_
type5public. A list of available datapoints is posted
on the study website under the heading ‘‘No
Committee Association.’’ For this study, we utilized
data from the following forms: Anthropometry Form,
Baseline Exacerbation Questionnaire, Baseline
Medical History Form, Demographic Form,
Modified Medical Research Council Dyspnea
Scale, Respiratory Disease and Smoke Exposure
Questionnaire, Spirometry Data Form, and Six
Minute Walk Test Form. Requested data only was
assembled into an appropriatedataset bythecentral
Data Coordinating Center and provided to the
investigators of this study. For requests, investiga-
tors should submit the Data Access and Request
Form found under the Heading ‘‘Data Sharing
Subcommittee’’ and forward to spiromics@unc.edu
such that an appropriate dataset can be assembled
by the data coordinating center, in the same way as
was provided to the authors of this study.
PLOS ONE | DOI:10.1371/journal.pone.0114438 December 16, 2014 1/1 4Results: Associations between comorbidities and all outcomes were comparable
across the three scores. All scores added predictive ability to models including age,
gender, race, current smoking status, pack-years smoked and FEV1 (p,0.001 for
all comparisons). Area under the curve (AUC) was similar between all three scores
across outcomes: SGRQ (range 0?7624–0?7676), MMRC (0?7590–0?7644), 6MWD
(0?7531–0?7560) and exacerbation risk (0?6831–0?6919). Because of similar
performance, the comorbidity count was used for external validation. In the
SPIROMICS cohort, the comorbidity count performed well to predict SGRQ (AUC
0?7891), MMRC (AUC 0?7611), 6MWD (AUC 0?7086), and exacerbation risk (AUC
0?7341).
Conclusions: Quantifying comorbidity provides a more thorough understanding of
the risk for patient-centered outcomes in COPD. A comorbidity count performs well
to quantify comorbidity in a diverse population with COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity
and mortality, recently becoming the third leading cause of death in the US. [1]
Comorbidities are common in COPD [2] and have been shown to be
associated with mortality, [3,4] poor quality of life [5–7] and worse health status.
[8]
Disease-specific instruments [9–11] for measuring comorbidity burden have
more utility for predicting clinical events and mortality than general instruments.
[12] The COTE (COPD specific comorbidity test) index was recently developed in
a COPD population to use comorbidities for predicting mortality, [3]a n d
another index was recently developed to describe general quality of life in COPD.
[13] Currently, there is no externally validated disease-specific comorbidity index
in COPD for predicting patient-reported clinical outcomes, particularly relevant
given the importance of patient-centered outcomes in chronic disease populations
such as COPD.
We hypothesized that the wealth of phenotypic data collected in the
COPDGene (Genetic Epidemiology of COPD) [14] and SPIROMICS
(Subpopulations and intermediate outcome measures in COPD study) [15]
studies would enable development and external validation of a score to
describe and quantify the impact of comorbidity burden on respiratory
disease-specific quality of life. This score could help clinicians with
prognostication and risk stratification of COPD in the clinic as well as serve as a
valuable research tool.
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Study population
COPDGene
COPDGene is a multicenter observational study of 10,192 current and former
smokers with 10 or more pack-years and age 45–80 years with and without
COPD. The study protocol and goals have been previously published. [14]
Participants were of non-Hispanic White or African-American race. Exclusion
criteria included lung disease other than asthma, lung resection or lung volume
reduction surgery, pregnancy, cancer being actively treated or suspected lung
cancer. We examined data of individuals with GOLD stages II-IV COPD (post-
bronchodilator spirometry with FEV1/FVC,0.7 and FEV1,80% predicted).
SPIROMICS
SPIROMICS [15] is a multicenter observational study recruiting smokers (with 20
or more pack-years smoking history) and non-smokers age 40–80 years with and
without COPD. We studied individuals recruited into SPIROMICS strata three
and four, which included mild through severe COPD (GOLD spirometry class I–
IV), based upon the presence of FEV1/FVC ratio of ,70% on post-bronchodilator
spirometry. Exclusion criteria for the study were non-COPD obstructive lung
disease, BMI.40 kg/m
2, history of lung surgery, or intolerance to bronchodila-
tors. Participant selection for both COPDGene and SPIROMICS studies is
depicted in S1 Figure.
Comorbidity assessment
We evaluated fourteen comorbidities, with comorbidity being defined as a
condition (disease or risk factor) requiring treatment or management while
having the potential of impacting ‘‘a person’s physical and emotional well-being.’’
[16] In both cohorts, comorbidities were assessed by self-report of physician
diagnosis with the exception of obesity, which was determined using measured
height and weight (S1 Table describes definitions of comorbidities). We included
some conditions considered to be risk factors for disease such as high cholesterol,
obesity and hypertension within our group of comorbidities. We included those
conditions which were present in 3% or more of the training cohort, also having
some amount of specificity(e.g. including sleep apnea but not cancer because
cancer reflects a broad spectrum of diseases with variable prognoses and
treatments).
Outcomes
The primary outcome of interest was respiratory disease-specific quality of life as
measured by St. George’s Respiratory Questionnaire(SGRQ), where higher scores
indicate worse health status. The SGRQ total score has been previously validated
[17], with a minimally important difference of four units. [18]
COPD Comorbidity Score
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protocol for six minute walk distance in feet, [19] dyspnea measured with the
validated modified Medical Research Council questionnaire (mMRC), [20] and
exacerbation risk. In both cohorts, individuals were classified as at risk for
exacerbations if they retrospectively reported at least one exacerbation in the past
year requiring change in medications, unscheduled visit to the doctor or
healthcare facility or hospitalization.
Statistical analyses
Population characteristics
We compared baseline characteristics of individuals with three or more
comorbidities to individuals with those having two or fewer comorbidities (given
three was the mean number of comorbidities in both cohorts) using t-tests and
chi-squared tests to calculate p-values for comparisons.
Comorbidity associations and score development using the COPDGene cohort
We tested individual associations of each comorbidity using regression models
with the primary outcome of interest, SGRQ, first unadjusted and then adjusted
for age, race, gender, FEV1 percent predicted, pack-years smoked and current
smoking status. We also performed backwards stepwise selection, locking in the
above adjusters, while simultaneously including all comorbidities, with criteria for
exclusion being a p-value of.0?2. We then developed three candidate
comorbidity scores for further comparisons:
1. A sum of number of comorbidities, with number of comorbidities determined
by available data on comorbidities in the cohort.
2. A weighted comorbidity score, where each comorbidity received a weight
based upon the coefficient from the models of adjusted association (all
comorbidities included)
3. A weighted comorbidity score, where only comorbidities left after the stepwise
selection procedure were included, and each included comorbidity received a
weight based upon the coefficient from the stepwise selection procedure
Internal validation
Once all three scores were developed, measures of discrimination and calibration
were computed within the same participants. For discrimination, we first fit an
‘‘empty’’ model without comorbidities that included only the covariates noted
above (age, race, gender, current smoking status, pack-years smoked and FEV1 %
predicted, described in Table 1) and calculated area under the curve (AUC). We
then computed AUCs of separate models including each comorbidity score
separately along with covariates. We compared the separate models (empty model
versus models with each separate score, then comparing each score to the other
using the ‘‘roccomp’’ command in Stata [21] to compute p-values for the
comparisons). We calculated Hosmer-Lemeshow (H-L) calibration statistics with
p-values to assess calibration, in this case a higher p-value indicates better
COPD Comorbidity Score
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group mean in order to utilize logistic regression models for calculation of AUCs
and H-L statistics. At the end of this step we reviewed the association and
validation data for all three scores and chose one score for external validation
steps based upon performance.
External validation using the SPIROMICS cohort
We computed the comorbidity score chosen from above steps in the first 853
COPD subjects recruited as part of the SPIROMICS cohort. High cholesterol,
stomach ulcers and peripheral vascular disease were assessed in COPDGene but
not in SPIROMICS. Accordingly these conditions were dropped from the score
for external validation only. We then computed measures of association (adjusted
regression models), discrimination (AUCs) and calibration (H-L statistics) as
described in the internal validation steps above, with regards to all described
outcomes (SGRQ, 6MWD, mMRC, exacerbation risk). Continuous outcomes
were dichotomized at their group mean (for validation cohort) in order to utilize
logistic regression models for calculation of AUCs and H-L statistics.
All analyses were performed using Stata 12 software package. [22] The
COPDGene and SPIROMICS studies were approved by Institutional Review
Boards at each clinical center and all participants provided written informed
consent, with centers and approval numbers listed in S1 Table. Both studies are
Table 1. Characteristics of participants with COPD based upon number of comorbidities.
COPDGene SPIROMICS
#2 comorbidites .2 comorbidities p-value #2comorbidites .2 comorbidities p-value
N 1,733 (47) 1,954 (53) 426 (50) 427 (50)
Age, years 62 (8.7) 65 (8.1) ,0?001 66 (7?9) 67 (7?6) 0?287
African American, n(%) 457 (26) 379 (19) ,0?001 54 (13) 53 (12) 0?907
Hispanic, n(%) NA NA NA 11 (3) 21 (5) 0?073
Pack-years smoked 50?0 (25?7) 55.6 (28.8) ,0?001 53?1 (25?5) 56?0 (27?6) 0?120
BMI, kg/m
2 25?7( 5 ?0) 30?1( 6 ?5) ,0?001 24?8( 3 ?8) 30?1( 5 ?0) ,0?001
Post-BD FEV1 percent
predicted
49?9 (19?2) 50?5 (16?8) 0?295 59?4 (23?7) 62?7 (22?1) 0?044
Current smokers, n(%) 851 (49) 649 (33) ,0?001 172 (40) 107 (25) ,0?001
MMRC dyspnea score 1?9( 1 ?4) 2?3( 1 ?4) ,0?001 1?1( 1 ?0) 1?2( 0 ?9) 0?126
6MWD, meters 374?6 (121?5) 343?2( 1 1 8 ?6) ,0?001 410?0 (107?1) 381?6( 1 1 5 ?9) ,0?001
SGRQ score 37?9 (22?4) 43?6 (21?1) ,0?001 34?4 (19?7) 36?4 (18?3) 0?152
Exacerbation in past yr,
n(%)
588 (34) 938 (48) ,0?001 106 (25) 124 (29) 0?214
Oxygen Therapy, n(%) 417 (24.1) 614 (31.4) ,0.001 50 (14.5) 110 (24.6) ,0.001
Use of Inhaled
Corticosteroids, n(%)
788 (46.5) 1,100 (57.1) ,0.001 140 (40.6) 196 (43.9) 0.34
Use of Oral
Corticosteroids, n(%)
87 (5.2) 123 (6.6) 0.09 10 (2.9) 20 (4.5) 0.24
All values as mean(SD) unless otherwise indicated.
doi:10.1371/journal.pone.0114438.t001
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(SPIROMICS) and NCT00608764 (COPDGene).
Results
Cohort characteristics and comorbidity burden
Characteristics of participants in the COPDGene and SPIROMICS study
populations were compared based upon presence of two or fewer versus three and
more comorbidities (Table 1). Individuals with more comorbidities had higher
BMI and had more cumulative smoking history but were less likely to be current
smokers. In the COPDGene population, individuals with more comorbidities
were older and less likely to be African American. Overall, prevalence of
comorbidities was comparable in the two cohorts, with the most prevalent
conditions being hypertension (51% and 50% in COPDGene and SPIROMICS,
respectively), GERD (30% in both cohorts) and obesity (33% and 32% in
COPDGene and SPIROMICS, respectively; S2 Table).
Association of comorbidities with SGRQ and score development
using COPDGene
We computed individual associations between each comorbidity and SGRQ,
adjusting for age, race, gender, FEV1 percent predicted, pack-years smoked and
current smoking status. All conditions are significantly associated with worse
health status (measured by SGRQ total score), with sleep apnea (8?83 points
higher on SGRQ scale, 95% CI 7?22–10?43), CHF (6?53 points higher, 95% CI
3?82–9?24) and GERD (6?45 points higher, 95% CI 5?11–7?78) having the
strongest negative impact on health status (S3 Table).
We formulated three candidate comorbidity scores as noted above: sum of the
number of comorbidities, weighted score, using coefficients from the individual
adjusted associations (S2 Table), and weighted score based upon selection
procedure. The average values of the scores were 2?9 (SD 2?1, range 0–11) for the
comorbidity count, 12?9 (SD 10?0, range 0–54.8) for the weighted score, and 6?2
(SD 5?3, range 0–29.6) for the weighted score from selection, with differences in
values reflecting differences in how the scores were constructed. All three scores
were significantly associated with higher SGRQ values (p,0?001). For example,
an increase in comorbidity count by one point was associated with an increase in
SGRQ by 2?31 points (95% CI 2?01–2?60; Table 2).
Internal validation
SGRQ
AUCs were significantly higher in models including comorbidity scores as
compared to the ‘empty’ model (p,0?001 for all comparisons). Discrimination
and calibration statistics of the three comorbidity scores were similar and each
performed reasonably well to predict SGRQ (for comorbidity count AUC 0?7624,
COPD Comorbidity Score
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p-value 0?66; for weighted score from selection AUC 0?7676, HL statistic 2?65, p-
value 0?95; Fig. 1).
Exacerbations, dyspnea, and exercise capacity
The three comorbidity scores were significantly associated with all secondary
outcomes (MMRC, 6MWD and exacerbations), with p-values for all comparisons
being ,0?001 (Table 3). For example, a one point increase in the comorbidity
count was associated with a 21% increased risk for an exacerbation (95% CI 1?17,
1?26), 20% increased risk for worse dyspnea score (95% CI 1?17, 1?24), and 10?6
fewer meters walked in six minutes (95% CI 212?1, 28?7). Discrimination was
slightly worse for these three outcomes compared to SGRQ, most notably for
exacerbations in which AUC ranged from 0?6831–0?6919. Calibration was
adequate except in the case of the weighted comorbidity score with regards to the
outcome of exacerbations. Sensitivity analysis was performed for the measures of
association, calibration and discrimination after excluding those reporting current
asthma from the population with COPD and the results were minimally changed
(data not shown).
External validation using the SPIROMICS cohort
Based upon the above results, we performed external validation of the
comorbidity count. Mean comorbidity count in the SPIROMICS cohort was 2?7
(SD 1?8), with range from 0–11 reflecting the three comorbidities not assessed in
SPIROMICS compared to COPDGene. The association of the comorbidity count
was strongly and significantly associated with all four outcomes (Table 4). A one
point increase in comorbidity count was associated with a two point increase in
SGRQ (95% CI 1?36, 2?63), a 16% increase in exacerbation risk (95% CI 1?04,
1?28), 23% risk for worse dyspnea (95% CI 1?13, 1?34), and 13?1 fewer meters
walked in six minutes (95% CI 217?3, 28?9). Calibration of the score was
appropriate for all outcomes (HL statistic p-value range 0?3849–0?9164) and the
comorbidity count performed well to discriminate differences in all four
Table 2. Mean, SD and adjusted associations of comorbidity scores and SGRQ value using COPDGene.
Mean (SD) Coefficient 95% CI p-value
Comorbidity count 2?9( 2 ?1) 2?31 (2?01, 2?60) ,0?001
Weighted comorbidity score 12?9 (10?0) 0?52 (0?45, 0?58) ,0?001
Weighted score from selection 6?2( 5 ?3) 1?00 (0?89, 1?11) ,0?001
Coefficients adjusted for age, race, FEV1, pack-years smoked, current smoking status and gender.
Equation for weighted comorbidity score: (4?93*coronary heart disease) + (4?69*diabetes) + (6?53*congestive heart failure) + (5?96*stroke) +
(5?13*osteoarthritis) + (4?31*osteoporosis) + (3?24*hypertension) + (2?14*high cholesterol) + (6?45*GERD) + (4?94*stomach ulcers) + (5*obesity) +
(8?83*sleep apnea) + (2?75*hay fever) + (3?71*peripheral vascular disease).
Equation for weighted score based on backwards selection: (2?16*coronary heart disease) + (1?39*diabetes) + (2?37*congestive heart failure) +
(4?71*stroke) + (2?35*osteoarthritis) + (3?29*osteoporosis) + (0?89*hypertension) + (4?13*GERD) + (2?48*stomach ulcers) + (2?69*obesity) + (6?49*sleep
apnea) + (1?20*hay fever).
doi:10.1371/journal.pone.0114438.t002
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PLOS ONE | DOI:10.1371/journal.pone.0114438 December 16, 2014 7/1 4Fig. 1. Areas Under the Curve (AUCs) for discrimination of comorbidity scores with regards to primary
outcome SGRQ. All three scores compared to ‘‘empty’’ model (including age, gender, race, FEV1, pack-
years smoked and current smoking status). ROC for empty model is 0.7393.
doi:10.1371/journal.pone.0114438.g001
Table 3. Discrimination measures (AUC) and calibration measures (Hosmer-Lemeshow calibration statistics) for comorbidity scores with regards to
exacerbations, MMRC, and 6MWD, using COPDGene.
Association with outcome AUC HL statistic p-value for HL statistic
Exacerbations OR 95% CI
Comorbidity count 1?21 (1?17, 1?26) 0?6831 13?24 0?1040
Weighted comorbidity score 1?044 (1?037, 1?052) 0?6880 20?35 0?0091
Weighted score from selection 1?09 (1?07, 1?10) 0?6919 11?02 0?2007
MMRC OR 95% CI
Comorbidity count 1?20 (1?17, 1?24) 0?7590 9?42 0?3078
Weighted comorbidity score 1?042 (1?037, 1?049) 0?7632 12?04 0?1494
Weighted score from selection 1?08 (1?07, 1?09) 0?7644 15?44 0?0511
6MWD b 95% CI
Comorbidity count 234?0( 239?6, 228?5) 0?7531 10?60 0?2253
Weighted comorbidity score 27?7( 28?9, 26?6) 0?7560 10?75 0?2161
Weighted score from selection 24?3( 25?0, 23?7) 0?7551 5?60 0?6919
Above models also include terms for age, gender, race, baseline FEV1, pack-years smoked and current smoking status. Every score above added to
‘‘empty’’ model, with addition of score improving AUC significantly (p,0?001 for all comparisons) with ROCs for empty models as follows: exacerbations
0.6542, MMRC 0.7423, 6MWD 0.7392.For associations with outcome, OR for exacerbations represents risk for exacerbation conferred by one point
increase in comorbidity score, OR for MMRC represents risk for worse dyspnea score conferred by one point increase in comorbidity score, and b for 6MWD
represents decrement in exercise capacity (in meters walked) conferred by one point increase in comorbidity score. All ROCs estimated using logistic
regression with outcomes of SGRQ (group mean 40.90, SD 21.89), MMRC (group mean 2.14, SD 1.41) and 6MWD (group mean 358.1, SD
121.0)dichotomized at group mean.
doi:10.1371/journal.pone.0114438.t003
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measures of discrimination, calibration and association with the weighted
comorbidity score and weighted score from selection to confirm that the
comorbidity count was a reasonable choice and found similar results as in the
COPDGene cohort (S4 Table). We performed sensitivity analyses dichotomizing
the continuous outcomes at the group mean for the COPDGene cohort for these
steps and the results of our analyses were minimally changed (data not shown).
Discussion
Using COPD cohorts of two large multicenter studies, we have developed a
COPD-specific comorbidity score which adds significant predictive ability to
models predicting clinical outcomes in COPD. A simple count of number of
comorbidities is a simplified way to quantify comorbidity in COPD and can be
easily applied to other cohorts of COPD with different characteristics and
spectrum of disease.
Accounting for comorbidity adds value to other known determinants of health
status in COPD. After adding the comorbidity count to a model already including
age, race, gender, lung function, current smoking status and cumulative smoking
history, the model discrimination for SGRQ improved with p-value of ,0.01 for
statistical comparison with base model. The comorbidity score improved the
prediction of health status, and three other outcomes of importance to patients
with COPD: dyspnea, exercise capacity and exacerbation risk. The addition of
comorbidities leads to changes in AUC values that may appear to be small.
However, the AUC is rather insensitive to model improvements and additional
predictors need to be strongly associated to change the AUC compared to a base
Table 4. Discrimination measures (AUC) and calibration measures (Hosmer-Lemeshow calibration statistics) for comorbidity count with regards to outcomes
of exacerbations, MMRC, and 6MWD, in the SPIROMICS participants.
Association with outcome AUC HL statistic p-value for HL statistic
SGRQ b 95% CI
Comorbidity count 2?00 (1?36, 2?63) 0?7891 3?50 0?8991
Exacerbations OR 95% CI
Comorbidity count 1?16 (1?04, 1?28) 0?7341 4?11 0?8472
MMRC OR 95% CI
Comorbidity count 1?23 (1?13, 1?34) 0?7611 8?51 0?3849
6MWD b 95% CI
Comorbidity count 213?1( 217?3, 28?9) 0?7086 3?27 0?9164
Above models also include terms for age, gender, race, baseline FEV1, pack-years smoked and current smoking status. Every score above added to
‘‘empty’’ model, with addition of score improving AUC significantly (p,0?001 for all comparisons). The AUCs for the empty models are as follows: SGRQ
0.7741, Exacerbations 0.7223, MMRC 0.7499, 6MWD 0.6970. For associations with outcome, OR for exacerbations represents risk for exacerbation
conferred by one point increase in comorbidity score, OR for MMRC represents risk for worse dyspnea score conferred by one point increase in comorbidity
score, and b’s for SGRQ and 6MWD represent decrement in health status and exercise capacity conferred by one point increase in comorbidity score. All
ROCs estimated using logistic regression with outcomes of SGRQ (group mean 35.4, SD 18.9), MMRC (group mean 1.18, SD 0.99) and 6MWD (group
mean 395.5, SD 112.5) dichotomized at group mean.
doi:10.1371/journal.pone.0114438.t004
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correlate with clinically relevant changes in classification and diagnosis of
individuals. [23] Indeed, the regression models (Table 2 and S4 Table) suggest
that comorbidities independently and strongly impact quality of life, dyspnea,
exercise capacity and exacerbation risk, when added to smoking, gender, lung
function, age and race. The fact that prediction is improved with the addition of
comorbidity is important and informative in this setting. Overall, it is the
combination of the findings of the strong associations in regression models with
the findings of the prediction steps of discrimination and calibration that
underscores the importance of comorbidity burden on patient-centered outcomes
in COPD.
Further, clinical studies of COPD are increasingly focused upon understanding
risk for clinical outcomes. Because individuals with COPD have a significant
burden of comorbidity [2,3,8] which appears to contribute to such poor clinical
outcomes, quantifying comorbidity burden is of importance in epidemiologic
studies and clinical trials. However, contribution of comorbidities to these
outcomes, including outcomes such as dyspnea and quality of life that are not
specific to COPD, may differ based upon the underlying chronic disease status.
For example, obesity may impact individuals with COPD by causing more airways
inflammation and change in lung volumes, whereas in a population with
cardiovascular disease obesity may have more impacts through metabolic
syndrome leading to endothelial dysfunction. Since it is likely that comorbidities
act through different mechanisms in different chronic diseases, there is value in
the development of a comorbidity score that is relevant to the specific population
of individuals with COPD. Validation of comorbidity score was less significant for
the predication of exacerbations because comorbidities likely have more impact
on the general markers of health such as dyspnea and quality of life, whereas
exacerbations are a disease-specific process related to COPD.
The burden of comorbidities can be established by a simple comorbidity count,
which requires no equation or complicated mathematical algorithm. As a result,
this kind of score is easy to apply in the clinical or research setting. Other general
and specific comorbidity indices require calculations using weights. [3,12] With
internal and external validation, important steps in proving the applicability and
reliability of prediction models, we have shown that a simple count of
comorbidities can perform just as well as a weighted score or score based upon
complicated statistical selection procedures.
Finally, we have shown that the comorbidity count not only predicts important
clinical outcomes in the COPDGene study population, when applied to a different
study population its predictive capability was equally strong. The SPIROMICS
study population used in this analysis differs slightly from COPDGene in that
participants are slightly older, with slightly better lung function and fewer current
smokers. Given that both studies include individuals from a broad range of COPD
severity with large percentage of African Americans and females, this scoring
system is broadly applicable in the real world setting across a range of COPD
severity, racial makeup, and gender. All of these characteristics demonstrate that
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on the population of at-risk smokers without COPD who are enrolled in both the
COPDGene and SPIROMICS cohorts and found that there may be utility of this
index in describing comorbidity in the at-risk population of smokers without
spirometric evidence of COPD, though our findings are predictably less robust in
at risk populations than in the population with COPD (S5 Table and S6 Table).
Our study has limitations. First, we relied on self-report to define most
comorbidities for this study. For large scale studies, assessment of comorbidity
using medical records is cumbersome and costly. The validity of self-report does
differ based upon the characteristics of the population studied and the
comorbidity considered [24–29] and should be considered when interpreting the
results of this study. In addition, we are limited by the lack of data on severity of
comorbidities, and have assessed them simply as present or absent. More
quantitative information on comorbidity severity including data on how
comorbidities are treated could have the potential to enhance the utility or
performance of such a score. Also, we did not include depression and anxiety as
comorbidities since these data were not available. The other existing comorbidity
index to predict generic quality of life, the COMCOLD index, [13] showed that
depression and anxiety are among the strongest predictors of health-related
quality of life. Additionally, if data on severity and treatment of comorbidities
were available its possible that a weighted score would have been more useful in
predicting outcomes. We also did not have data on cognitive impairment, an
increasingly recognized comorbidity of the COPD population. [30] Further,
though mental illness such as depression and anxiety were assessed in
SPIROMICS, lack of data on this comorbidity in COPDGene limited our ability
to include it in our index. However, when we incorporated these conditions for
the external validation steps (requiring recalibration of the index specific to the
SPIROMICS population), the comorbidity count continued to be comparable to
the more complicated comorbidity index measures (data not shown). Further,
lack of data on mental illness, as well as insufficient data on malignancies in
COPDGene limited our ability to compare the performance of the comorbidity
count to indices of comorbidity in COPD such as the COTE index. Finally, we
have constructed and validated this score in a broad range of COPD patients.
However, given the increasingly recognized heterogeneity of COPD and the
likelihood that some comorbidities are more common in subsets of COPD
patients [31], it is possible that our score may perform slightly better or worse in
any one subset of COPD patients. In addition, because of the variability and
inconsistency in the comorbidities assessed in these two study populations, it was
impossible to formulate and validate an index with specific cutoffs for the
prediction of clinical endpoints in COPD. Moving forward the next step would be
to develop and externally validate such an index in study populations with
consistent data on a broad range of comorbidities, testing cutoffs for the
prediction of relevant clinical outcomes such as quality of life and dyspnea.
Our study did have several strengths. First, these results derive from two large,
multicenter, well-characterized and fairly representative populations of indivi-
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comorbidity in COPD can be quantified with such ease has the potential to
improve and simplify the measurement of comorbidity in future studies and thus
can have far-reaching effects. Next, we have focused upon clinically-relevant
outcomes, which are important to patients with chronic disease such as COPD.
Finally, by validating our score internally and externally we have undertaken an
important step not demonstrated before in the COPD comorbidity literature.
Conclusions
We have shown that a comorbidity count in individuals with COPD is not only
simplified, but when added to known risk factors is also predictive of important
outcomes such as health status, dyspnea, exercise capacity and exacerbation risk.
Moving forward, validation of a similar index in populations with a broad range
of COPD severity could add generalizability and validity to our preliminary
findings that a comorbidity count is a simple and relevant way to quantify
comorbidity burden in COPD. Ultimately, such an index can have broad
applicability to help quantify comorbidity burden in COPD clinical research.
More importantly, such a score can assist clinicians to identify populations with
COPD at risk for poor health related outcomes, so that interventions that improve
quality of life, dyspnea and exercise capacity, such as rehabilitation, can be
considered earlier.
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